| |
IQVIA experts evaluate epidemiological variances for indication-specific distribution to better-inform diversity goals for clinical trials. Download the white paper.
|
|
| By Annalee Armstrong This year's Fierce 15 features companies pushing the envelope not only in the lab, in the clinic or on the conference circuit. |
|
|
|
By Zoey Becker The company cited concerns with the law's consequences for orphan drug development. AstraZeneca becomes the sixth drugmaker to file suit against the IRA. |
By Nick Paul Taylor Novo Nordisk is continuing to seek out obesity assets, paying 15 million euros ($16 million) to snap up Embark Biotech in its second weight loss takeover in quick succession. |
By Fraiser Kansteiner The drugs that made the cut for the first price negotiations are Johnson & Johnson’s Imbruvica, Stelara and Xarelto plus Bristol Myers Squibb’s Eliquis, Merck & Co.’s Januvia, Novartis’ Entresto, Eli Lilly’s Jardiance, AstraZeneca’s Farxiga, Novo Nordisk’s Fiasp and Amgen’s Enbrel. |
|
Tuesday, September 5th, 2023 | 10am ET / 7am PT Process chemistry plays a pivotal role in various stages of the pharmaceutical R&D cycle. However, support for preclinical and early clinical phases demands a delicate balancing act. Join us as we explore critical process chemistry issues that commonly arise to unlock the secrets for streamlining drug development and paving the way to successful IND submissions. Register now.
|
|
By Gabrielle Masson Notch Therapeutics is shuttering one of its three cell therapy centers—which also serves as its headquarters—and is working to find positions for its displaced staff at other companies in the industry. |
By Fraiser Kansteiner Danaher Corporation is picking up all outstanding shares of Abcam for $24 apiece. Both companies’ boards unanimously approved the decision, Danaher and Abcam said Monday. The deal is expected to close in mid-2024. |
By Nick Paul Taylor Merck & Co. is betting big on its oral PCSK9 inhibitor. Buoyed by midphase results, the Big Pharma has kicked off a clutch of late-stage studies including a cardiovascular outcomes trial that will follow patients for around six years. |
By Kevin Dunleavy Right after joining a Cellares funding round, Bristol Myers Squibb plans to utilize the cell therapy manufacturer’s robotic platform. For evaluation, Cellares will perform a proof-of-concept transfer process for the manufacture of a BMS pipeline cell therapy. |
By Ben Adams For 22 years, pharma manufacturer and service company AmerisourceBergen has been the bane of pharma journalists with its very long-winded and bolt-on name, but, at last, our fingers can get a rest. |
By Helen Floersh New research that helps explain why KRAS mutations drive pancreatic cancer suggests that monotherapy isn’t sufficient to eliminate it—but that combining KRAS inhibitors with immunotherapy might be the key. |
By Andrea Park Theken Companies, an Ohio-based family of medical implant makers, has found the next member of its family within the Buckeye State. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we discuss the trends seen at Cannes Lions, the top compensated CEOs in the industry, and the cancer drug shortage |
|
|---|
|
|
|
Wednesday, September 6, 2023 | 2:00 PM ET / 11:00 AM PT Attendees will learn about the latest tools for interacting with medical images, how to guide readers through labeling workflows, and streamlining adjudication and data standardization. Discussions will include real-world use cases of how pharma companies are enhancing AI development by optimizing reader workflows. Register now.
|
|
| WhitepaperLearn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
| WhitepaperLearn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
| Whitepaper15 biotech executives from the Cambridge area discuss the current biotech landscape, as well as challenges, opportunities, and best practices for emerging biotech companies seeking success in the UK and beyond. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| WhitepaperUnravel the intricacies of Cell Line Development in biotherapeutics production with our latest eBook chapter. Sponsored By: Danaher Life Sciences |
| WhitepaperLearn how process liquids and buffers impact your total cost of ownership (TCO) and how outsourcing can revolutionize your approach, ensuring quality standards and improving productivity. Sponsored by: Thermo Fisher Scientific Process Liquid Preparation Services |
| WebinarDownload this webinar to learn how to avoid pitfalls when characterizing CAR-T cells in your development workflow, how to save time by using one antibody to examine your entire panel of CARs, and more. Sponsored by: Cell Signaling Technology |
| |
|
